top of page
Deep Creek Pharma
Next-generation fluoropyridines
Deep Creek Pharma is an oncology therapeutics company spun out of the Wake Forest University School of Medicine, and is developing CF10, a next generation fluoropyrimidine. CF10 is engineered for direct tumor-active metabolite formation and designed to improve upon fluorouracil, the chemotherapy backbone used across colorectal cancer and other solid tumors. The Company is in late pre-clinical stage and intends for the first indication to be metastatic colorectal cancer (mCRC) with liver metastases.
“In published in vivo data, CF10 dramatically extended survival versus 5-FU.
5-FU reached 0% survival by 37 days, while CF10 maintained 50% survival through 90 days.”
(Mol Cancer Ther 2021)
Home: Welcome
bottom of page